See Our Winners, Runners Up & Shortlisted
The 2024 winners and runners-up were announced during a special ceremony taking place at the 15th World ADC San Diego.
Best ADC Platform Technology
Winner:
LigaChem Biosciences ConjuAllTM
Runner Up:
Catalent SMARTag
Shortlisted:
- Abzena - ThioBridge
- Ajinomoto Biopharma Services- AJICAP
- Daiichi Sankyo - DXd ADC Technology
- Sichuan Kelun-Biotech - optiDC
- WuXi XDC -WuXiDAR4 Platform
Most Promising Clinical Candidate
Co-Winners:
Raludotatug Deruxtecan, Daiichi Sankyo and Ifinatamab Deruxtecan, Daiichi Sankyo
Shortlisted:
- BL-B01D1 – SystImmune,
- MBRC-101 - MBrace Therapeutics
- OBI-992 - OBI Pharma,
- Sacituzumab Tirumotecan - Sichuan Kelun-Biotech/ MSD
Best New Drug Developer
Winner:
Duality Biologics
Runner Up:
ProfoundBio (Genmab)
Shortlisted:
- Exelixis
- LigaChem Biosciences
- MBrace Therapeutics
- Sichuan Kelun-Biotech
Best Contract Manufacturing (CDMO) Provider
Co-Winners:
Lonza and WuXi XDC
Shortlisted:
- AsymBio
- Aton Biotech
- BSP Pharmaceuticals
- Cerbios AG
- MilliporeSigma
- Simtra BioPharma Solutions
Best Contract Research (CRO) Organization
Co-Winners:
NJ Bio Inc. and PPD
Shortlisted:
- Abzena
- ChemExpress
- Crown Bioscience
- WuXi XDC
Best ADC Prelinical Publication 2023
Winner:
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production
Runner Up:
Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
Best ADC Clinical Publication
Winner:
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Runner Up:
Trastuzumab Deruxtecan Versus Treatment of Physician's Choice in Patients with HER2-Positive Metastatic Breast Cancer (DESTINY-Breast02): a Randomised, Open-Label, Multicentre, Phase 3 Trial
Best Poster 2024
Winner:
Tub-040, a Novel napi2B-Targeting ADC Built With Ethynylphosphonamidate Conjugation Chemistry, Demonstrates High and Long-Lasting Anti-tumor Efficacy via Topoisomerase I Inhibition and Excellent Tolerability Predictive of a Wide Therapeutic Window in Humans
The George R. Pettit Individual Input to the Field
Co-Winners:
Andrew Polson, Genentech and Brian Mendelsohn, Exelixis
Outstanding Academic Investigator Award
Winner:
Joseph Balthasar, University at Buffalo
Long Standing Contribution to the Field
Winner:
Morris Rosenberg
Explore World ADC San Diego's Agenda
Discover the latest industry breakthroughs and insights to be shared at the biggest ADC event, ahead of the awards' gala.
Partner With Us
Position yourself in front of the pioneers trailblazing ADCs to standard of care treatments.
Submit Your Nominations
Have your say on who gets recognized this year because of their exceptional work propelling the ADC field to new heights.